Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 6
2010 5
2011 4
2012 3
2017 1
2018 1
2019 2
2020 1
2021 2
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D; SOLAR-1 Study Group. André F, et al. N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, Xu B, Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M, Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131 investigators. Miles D, et al. Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1. Ann Oncol. 2021. PMID: 34219000 Free article. Clinical Trial.
Tamoxifen and arrhythmia.
Slovacek L, Priester P, Petera J, Kopecky J. Slovacek L, et al. Among authors: priester p. Med Oncol. 2010 Dec;27(4):1431-2. doi: 10.1007/s12032-009-9334-5. Med Oncol. 2010. PMID: 19844815
[Changes in immune reactivity in cancer patients].
Kopecký J, Slováček L, Priester P, Slováčková B, Kopecký O. Kopecký J, et al. Among authors: priester p. Klin Onkol. 2012;25(2):97-102. Klin Onkol. 2012. PMID: 22533883 Review. Czech.
Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma.
Kopecky J, Kubecek O, Priester P, Vosmikova H, Cermakova E, Kyllarova A. Kopecky J, et al. Among authors: priester p. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Dec;166(4):393-404. doi: 10.5507/bp.2021.053. Epub 2021 Aug 24. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022. PMID: 34446937 Free article.
Cancer and depression: a prospective study.
Slovacek L, Slovackova B, Slanska I, Priester P, Petera J, Kopecky J, Vanaskova J. Slovacek L, et al. Among authors: priester p. Neoplasma. 2009;56(3):187-93. doi: 10.4149/neo_2009_03_187. Neoplasma. 2009. PMID: 19309220
28 results